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Spinal muscular atrophy is an autosomal recessive
disorder which affects about 1 in 10 000 individuals.
The three clinical forms of SMA were mapped to the
5q13 region. Three candidate genes have been
isolated and shown to be deleted in SMA patients: the
Survival Motor Neuron gene (SMN), the Neuronal
Apoptosis Inhibitory Protein gene (NAIP) and the
XS2G3 cDNA. In this report we present the molecular
analysis of the SMN exons 7 and 8 and NAIP exon 5 in
65 Spanish SMA families. NAIP was mostly deleted in
type I patients (67.9%) and SMN was deleted in 92.3%
of patients with severe and milder forms. Most patients
who lacked the NAIP gene also lacked the SMN gene,
but we identified one type II patient deleted for NAIP
exon 5 but not for SMN exons 7 and 8. Two other
patients carried deletions of NAIP exon 5 and SMN
exon 7 but retained the SMN exon 8. Three
polymorphic variants from the SMN gene, showing
changes on the sequence of the centromeric
(cBCD541) and telomeric copies of the SMN gene, were
found. In addition, we show several genetic
rearrangements of the telomeric SMN gene, which
include duplication of this gene in one normal
chromosome, and putative gene conversion events in
affected and normal chromosomes. Altogether these
results corroborate the high genetic variability of the
SMA region. Finally, we have determined the ratio
between the number of centromeric and telomeric
copies of the SMN gene in parents of SMA patients,
showing that the majority of parents of types II and III
patients carried three or more copies of the cBCD541
gene; we suggest a relationship between the number
of copies of cBCD541 and the disease phenotype.
INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal recessive disorder
with an overall incidence of 1 in 10 000 and a carrier frequency of
about 1/40 (1). This neuromuscular disease is characterized by the
degeneration of the α motor neurons of the spinal cord, which leads
to progressive symmetrical weakness and wasting in the proximal
muscles. Three types of SMA have been distinguished on the basis
of clinical severity and age of onset. Type I is the most severe form,
affected individuals cannot sit unaided and death occurs before 2
years; type II is the intermediate form, with early onset and inability
to walk; type III corresponds to the mild form and patients achieve
the ability to walk (2).
A locus for the three clinical forms of SMA was mapped to
chromosome 5q11.2-q13.3 by linkage analysis (3–6). Charac-
terization of recombinational events with closer polymorphic
markers contributed to narrow the SMA locus genetic interval
(7–10).
Five YAC contigs spanning the SMA region have been
constructed (8,11–14) but physical mapping has been hampered
by the instability of this chromosomal region probably due to the
presence of many repeated sequences (8,11,15,16). Furthermore,
it has been found to contain a large inverted duplication (17) and
several classes of expressed pseudogenes (18,19). This complex
genomic organization complicated the identification of the SMA
gene. Recently, three SMA candidate cDNAs have been reported,
the Survival Motor Neuron (SMN) gene (17), the Neuronal
Apoptosis Inhibitory Protein (NAIP) gene (20) and the XS2G3
cDNA (21).
Two copies of the SMN gene, centromeric (cBCD541) and
telomeric (SMN) have been identified. They are virtually
identical at their genomic sequence (only five nucleotide changes
along 20 kb) and both are transcribed (17). It has been reported
that most SMA patients (98.6%) were homozygous for deletions
of the SMN telomeric copy, but no specific mutations explaining
the three SMA phenotypes have been found (17,22).
The NAIP gene shows similarity with baculoviral genes
involved in inhibition of apoptosis in infected insect cells (20).
One NAIP full copy and several truncated copies are present in
the SMA region. Specific exons of NAIP were deleted in 45% of
type I patients and 18% of types II and III, but also in 2% of
unaffected carrier individuals. Thus, loss of NAIP is not sufficient
to cause the disease.
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Table 1. Analysis of NAIP and SMN genes in Spanish SMA patients
Genotype Type I Type II Type III Total
SMN NAIP
Exon 7 Exon 8 Exon 5
– – – 18 (64.3%) 2 (7.1%) 2 (22.2%) 22 (33.8%)
– – + 9 (32.1%) 20 (71.4%) 6 (66.7%) 35 (53.8%)
– + – 1 (3.6%) 1 (3.6%) 2 (3.1%)
– + + 1 (11.1%) 1 (1.5%)
+ + – 1 (3.6%) 1 (1.5%)
+ + + 4 (14.3%) 4 (6.1%)
Total 28 28 9 65
(–) and (+) denote absence or presence of exon, respectively
As NAIP, the XS2G3 cDNA detects homozygous deletions in
more than 50% of type I patients but also in parents of SMA
individuals (21). In fact, the XS2G3 sequence is complementary
to NAIP exon 7 and flanking intronic sequences (23).
In this study we have screened our SMA patients for deletions
of NAIP and SMN genes. We have also characterized several
SMN polymorphic variants and other genetic rearrangements that
further illustrate the variability of this region. Finally, we have
determined the cBCD541/SMN dose ratio in our set of parents of
SMA patients, and we have correlated it with the SMA
phenotype.
RESULTS
Analysis of NAIP gene
To detect individuals carrying deletions of NAIP, a multiplex
PCR reaction to amplify exon 5 (specific of NAIP), exon 13
(existing in both NAIP and in a truncated form of NAIP) and
microsatellite D5S1416 (as internal control) was carried out as
described in Materials and Methods. Thus 65 SMA affected
individuals were analyzed for deletion of NAIP exon 5 (Table 1).
The deletion frequency was 38.5% (67.9% in type I patients,
14.3% in type II and 22.2% in type III). Analysis of parents was
also performed and we found four of 123 carrier individuals
(3.2%) homozygously deleted for NAIP exon 5.
Analysis of SMN exons 7 and 8
SSCP analysis of PCR products was carried out to differentiate
between centromeric and telomeric copies of SMN exons 7 and
8 (Fig. 1a, b). Table 1 summarizes the result of the screening of
the 65 SMA individuals. Fifty-seven (87.7%) of total SMA
patients (96.4% of type I, 78.5% of type II and 88.9% of type III)
lacked the telomeric bands of SMN exons 7 and 8, and the
telomeric exon 7 was absent in three patients who retained at least
one copy of telomeric exon 8. Consequently the telomeric SMN
gene was altered in 92.3% of patients. However, all patients
carried centromeric copies of both exons.
Five type II patients retained at least one copy of the SMN
telomeric gene. One of them carried the normal telomeric exon 7
and the BsmAI telomeric variant described below; another one
only retained the BsmAI variant (lane 7 of Fig. 1a), and another
patient lacked NAIP exon 5. The remaining two patients retained
at least one copy of an apparently normal telomeric SMN gene.
Figure 1. SSCP gels showing telomeric and centromeric copies of (A) SMN
exon 7, lane 4, SMA carrier individual; and (B) SMN exon 8, lanes 1 and 6,
control individuals. Arrows: t, telomeric copy; c, centromeric copy; b,
SMN-2BsmAI variant; and ∆AT, SMN-2∆AT polymorphism of exon 8.
SMN exons 7 and 8 analysis of 120 healthy parents of SMA
patients (54 of type I, 50 of type II and 16 of type III) did not show
any individual homozygous for deletion of telomeric exon 7, but
two showed no telomeric copies of exon 8. In addition, four
parents (3.3%; two of type I and two of type II) lacked the
centromeric exons 7 and 8. Parents lacking telomeric exon 8 were
further investigated. We amplified SMN exon 8 with another pair
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of flanking primers (SMN8-D and SMN8-E) and then PCR
products were digested with DdeI which only cleaves the
centromeric copy. Once more, no telomeric PCR products were
obtained; therefore, the non-detection of telomeric exon 8 was not
a PCR amplification failure. Furthermore, in one of these parents,
amplification from exon 7 to exon 8 (primers SMN78-F at
intron 6 and SMN78-R at exon 8) and sequencing analysis of
these products, revealed a hybrid SMN gene composed of
telomeric exon 7 and centromeric exon 8 on his non-affected
chromosome. This hybrid gene might result from a gene
conversion event.
SSCP polymorphic variants
We have detected several polymorphic variants of the SMN gene
by SSCP analysis. The exon 7 PCR product of one SMA patient
showed an altered band and no telomeric one. His unaffected
father presented an identical SSCP pattern except that he was
probably homozygous for this variant (lanes 5 and 7 of Fig. 1a).
Two haploidentical unaffected siblings who inherited the paternal
affected chromosome also showed the variant (lanes 8 and 9). A
similar SSCP variant of exon 7 was detected on another
unaffected father, in this case the altered band did not segregate
with the disease phenotype as the affected sib was homozygously
deleted for SMN exon 7 (result not shown). Sequence analysis of
exon 7 PCR products from two individuals carrying this SSCP
variant (Fig. 2a; SMN-2BsmAI) showed an A→G transition on the
telomeric copy, 96 bp upstream of the 3′ end of intron 6, which
created a novel BsmAI restriction site. BsmAI restriction
digestion of exon 7 PCR products allowed us to estimate the
frequency of the SMN-2BsmAI polymorphism as 2% in normal
population.
One variant at exon 7 (cBCD541–2892g→c) was detected on the
normal chromosome of an unaffected carrier. This SSCP band
moved near the normal exon 7 telomeric one (result not shown).
It was a centromeric copy carrying a G→C transition at the 892
position of the cDNA (Fig. 2a), changing a glycine to arginine.
This polymorphism was found only once after analyzing 30
control and 120 carrier individuals.
Sequence analysis of PCR products from exon 7 revealed a
non-polymorphic intronic difference between centromeric and
telomeric copies, a Gtel↔Acen change, 44 bp upstream of the 3′
end of intron 6 (arrows in intron 6 of Fig. 2a). Probably, this is one
of the three intronic differences between SMN and cBCD541
reported by Lefebvre et al. (17).
For exon 8, we detected a novel SSCP variant in a female carrier
(Fig. 1b). Our sequence analysis of exon 8 PCR products from this
woman and control individuals (Fig. 2b) revealed that the normal
centromeric and telomeric SSCP bands had two nucleotide changes
with respect to the previously published sequence (17) resulting in
an AluI restriction site (ATGAGCT) instead of the predicted HaeIII
site (ATGGCCT). The presence of the AluI and the absence of the
HaeIII sites were confirmed in 50 control individuals. The
sequences obtained in this work are called cBCD541-2 (centromeric
copy) and SMN-2 (telomeric copy) in Fig. 2b. To clarify the
nomenclature, we have renamed the previously published sequences
as cBCD541-1 (centromeric copy) and SMN-1 (telomeric copy).
Furthermore, all clones from normal centromeric (cBCD541-2) and
telomeric (SMN-2) bands have two basepairs more (‘AT’ at position
43 of the exon 8 PCR product) than the published sequence for
cBCD541-1 and SMN-1 (17).
Figure 2. Sequence of centromeric, telomeric and polymorphic variants of (A)
SMN exon 7; and (B) SMN exon 8. Capital letters denote exonic sequences,
arrows mark the differences between centromeric and telomeric copies,
restriction sites are shaded, and asterisks mark the polymorphisms. SMN-1 and
cBCD541–1 are the previously published sequences (17), and SMN-2 and
cBCD541–2 are the sequences from the telomeric and centromeric copies of
SMN, respectively, obtained in this work.
Finally, the polymorphic SSCP band detected in the female
carrier matches the reported sequence of SMN exon 8 (SMN-1),
except that it also includes the AluI change. So, this variant can
be considered as an AT deletion of SMN-2, and we called it
SMN-2∆AT. In fact, when PCR products of exon 8 from control
individuals and other ones carrying the SMN-2∆AT variant were
loaded on 6% native polyacrylamide gels, two bands of different
molecular weight were visualized, the variant corresponding to
the band of lower molecular weight (result not shown). This
polymorphism was found in one of 120 carrier individuals and
one of 30 control individuals.
The SMN-2∆AT polymorphism was detected in a woman
requesting prenatal diagnosis (lane 3 of Fig. 1b). Her affected type
II SMA son lacked telomeric copies of exons 7 and 8 (lane 4).
Mother and fetus had the bands corresponding to SMN, cBCD541
and the exon 8 variant (lanes 3 and 5). Genotyping of this family
with 5q13 markers indicated that the fetus carried the affected
paternal chromosome and the normal maternal one (see haplo-
types in Fig. 1b). Thus, the extra-SSCP band segregated with the
telomeric one. Amplification from exon 7 to exon 8 and
sequencing analysis showed that the SMN-2∆AT variant of exon 8
was linked to a telomeric exon 7. So the mother and the fetus
normal chromosomes seem to carry two telomeric SMN genes.
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The pregnancy proceeded at term and in the immediate postnatal
period the baby appeared clinically unaffected.
Densitometric analysis of SMN exon 7 in parents of
SMA patients
In the screening of SMN exons 7 and 8 by SSCP analysis of
parents of SMA patients we detected remarkably strong signals
corresponding to the centromeric copies on several individuals.
Since we use the same primer set and the same template for
amplifying centromeric and telomeric exons, and since the sizes
of both products are identical, then it is possible to quantitate the
relative amounts of cBCD541 and SMN exon 7 by densitometric
analysis of the SSCP bands. All of the parents of affected
individuals who lacked the telomeric exon 7 were analyzed. We
assumed that these parents had only one copy of SMN and thus
the cen/tel dose ratio could reflect the number of copies of
cBCD541. A set of control individuals (Fig. 3a) was also
analyzed, but it must be stressed that these individuals probably
carry two copies of SMN and so, the same cen/tel dose ratio of
exon 7 in both cases (control and carrier individuals) does not
represent the same number of cBCD541 copies.
Results of this analysis are shown in Figure 3b. Two observa-
tions should be pointed out. First, 18.5% of parents of type I
patients had a cen/tel dose ratio of 1:1. Given that their affected sibs
were homozygously deleted for telomeric exon 7, this result
suggests that parents carried a large deletion spanning cBCD541
and SMN in one chromosome. Also, parents with a dose ratio of
1:1 could carry two copies of each gene, and then the loss of SMN
in their affected children could be due to de novo deletions. These
families were further investigated by genotyping the multiloci
polymorphic marker C272 (12) which lies in the 5′ end of the SMN
gene. Segregation analysis did not demonstrate any de novo
rearrangement. Furthermore, only two amplification products of
C272 were detected in nine out of 10 parents with a dose ratio of
1:1 (data not shown). Second, in parents of types II and III patients,
the cen/tel dose ratio is clearly biased towards higher values being
significantly different from parents of type I (χ2 = 26.74, d.f. = 6,
p <0.0002). Furthermore, parents of types II and III who had an
increased dose of centromeric exon 7 showed a similar dose of
centromeric exon 8. Although parents of type III seemed to have
more copies than parents of type II, the small size of our type III
sample did not permit us to establish significant differences
between them (χ2 = 4.30, d.f. = 6, p = 0.63). Altogether these
results indicate that the number of copies of cBCD541 is quite
variable (0 to 4 or more copies per diploid genome) and suggest
that there would be a higher number of cBCD541 copies in patients
of types II and III than in those of type I.
DISCUSSION
Two different genes (NAIP and SMN) have been recently
reported to be associated with the SMA disease (17,20). We have
performed a genetic study of these genes in our SMA families to
try to understand their respective roles in SMA.
The similarity found between NAIP and the baculoviruses
inhibitory apoptosis proteins (IAPs) implicates the NAIP gene in
the pathological mechanism which causes motor neuron
depletion, probably by alteration of the neuronal apoptotic
pathway (24). We have found that NAIP exon 5 is mostly deleted
in type I patients at a frequency slightly higher than that
previously reported (67.9% versus 45%) (20). The majority
Figure 3. cBCD541/SMN dose ratio in (A) controls and (B) parents of SMA
patients. 0–0.5, represents individuals carrying no copies of cBCD541 (6.7% of
controls, 3.7% of parents of type I and 4.7% of parents of type II), or individuals
who probably carry two copies of SMN and one copy of cBCD541 (13.3% of
controls); 1, represents one copy of cBCD541 and it has been considered cen/tel
values between 0.5 and 1.5; 2, two copies, values 1.5–2.5; 3, three copies, values
2.5–3.5; 4; four copies, values 3.5–4.5; and 5, five copies, values 4.5–5.5.
(96%) of our patients who lacked NAIP exon 5 also lacked SMN.
However we found one type II patient who lacked NAIP exon 5
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but retained the SMN exons 7 and 8. Also, four parents of SMA
individuals were homozygously deleted for NAIP exon 5 but
retained SMN. Thus, NAIP deletions are not always associated
with SMN deletions as has been suggested (17).
NAIP deletions are not a general finding in types II and III SMA
patients, but the existence of other kind of mutations cannot be
excluded as they have not been tested for. It is conceivable that
mutations on both genes (NAIP and SMN) must account for SMA
disease. Indeed, it has been reported that genes involved in the
apoptosis pathway of Drosophila melanogaster are functionally
redundant, with one sometimes compensating for the loss of the
other (25). So, mutations in two genes (reaper and hid) which lie
in the same genomic region are required to obtain apoptosis-de-
fective mutant flies.
The majority of our SMA patients lacked SMN (92.3%) thus
corroborating that it is a SMA-determining gene (17,22). The
high genetic variability of this gene is also shown in this work. We
found a putative gene conversion event in two normal chromo-
somes from parents of SMA patients who had a hybrid SMN gene
containing an exon 7tel-exon 8cen instead of the normal structure.
Since the exon 8 is untranslated, it is plausible that this hybrid
gene might be fully functional. Also, a putative SMN duplication
was found in one normal chromosome which had a normal SMN
copy and another polymorphic copy (SMN-2∆AT polymorph-
ism). Furthermore, we have characterized three polymorphic
variants of this gene. One of them, the SMN-2BsmAI polymorph-
ism at intron 6, segregates with the disease in two patients. This
change would create a putative new 5′ splice site in intron 6
(GTGAG; consensus sequence gGTRAG) (26). Whether this
change affects the splicing of SMN can be determined only by
mRNA studies. However, hemizygous or homozygous parents
for this variant are phenotypically normal, therefore we can
conclude that it is not a mutation causing disease and patients
harboring this polymorphism must carry another mutation in their
SMN gene. The remaining polymorphisms, the SMN-2∆AT at
exon 8 and the cBCD541–2892g→c at exon 7, migrate very close
to the normal telomeric bands. Therefore, a careful SMN analysis
must be conducted to detect all the possible variants. Our analysis
has permitted us to distinguish these variants and it has avoided
false conclusions in the genetic analysis of our SMA families.
There are two patients (one type I, one type II) carrying
deletions in SMN exon 7 and NAIP exon 5 but not in SMN exon
8. Taking into account the relative positions of these two genes
(SMN exon7-SMN exon 8-NAIP exon 5) reported by Lefebvre
et al. (17) and Wirth et al. (27), there are three possible
explanations for the genetic rearrangements detected in these
patients. First, the position of NAIP is wrong, being proximal to
SMN. Second, deletions of NAIP and SMN are two unrelated
rearrangements, but the physical proximity of the two genes
argues against this possibility. Third, the presence of exon 8tel in
these patients may be equivocal. These patients might have both
NAIP and SMN deleted, and have a ‘cBCD541’ gene containing
an exon 7cen-exon 8tel, generated by a gene conversion event.
The role of cBCD541 is still unknown. Occasionally,
unaffected individuals lacking the centromeric copies of SMN
have been identified (17,22). We also found four parents of SMA
individuals without cBCD541. However, homozygous deletions
of the cBCD541 gene were never detected in SMA patients
lacking SMN, due presumably to the nonviability of these
individuals as has been previously suggested (17).
Our densitometric analysis of the SMN gene carried out in
parents of SMA patients, indicated that the number of the
centromeric copies is variable (0–4 or more copies per diploid
genome) and higher in parents of types II and III patients than in
parents of type I. In this analysis we assumed that SMN deletions
in SMA patients were inherited from their parents. However, de
novo deletions can also occur in this chromosomal region, but we
consider that this parameter does not affect the global results of
our analysis because of the low frequency of this rearrangement
[a total of seven de novo deletions in 461 families (12,27,28)]. It
should be noted that the proportion of parents of type I with a
cBCD541/SMN dose ratio of 1:1 was 18.5%, which could
represent one or two copies of each gene. In the case of parents
with two copies of SMN, the loss of this gene in their affected
children could be due to de novo deletions involving SMN.
However, by segregation analysis of the multiloci microsatellite
C272 in these families we have not detected such de novo
deletions. Moreover, in nine out of 10 parents we have found only
two amplification products of C272, and consequently they
probably carry a large deletion spanning cBCD541 and SMN in
the affected chromosome. Also, we found 50% of parents of
type I SMA patients who had two copies of cBCD541. These
individuals would carry an affected chromosome with a deletion
which only involves the SMN gene. All these findings are
correlated with a high frequency of type I patients who lacked
NAIP exon 5 (67.9%; frequency of deletion 82.4%). Therefore,
deletions would be the most frequent phenomenon in type I
patients, as has been indicated by several authors (12,27,28). It
has been reported that 50% of type I patients carried only one
copy of the C212 and Ag1-CA (C272) multiloci markers on each
chromosome (27). The C212 marker maps proximal and close to
the SMN gene and the Ag1-CA lies at the 5′ end of the SMN gene.
Taking into account that SMN is deleted in these patients, it could
be inferred that the number of copies of these markers reflects the
gene dose of cBCD541. This analysis is in agreement with the
high frequency of parents of type I in our sample who retained
two copies of cBCD541.
Our study shows that 66.5% of parents of type II and 75% of
type III appeared to have at least three copies of cBCD541. Once
again, this result is in agreement with the analysis of the multiloci
markers cited above (27) which indicated that majority of types
II and III patients would carry one copy of these markers in one
chromosome, and two copies in the other one.
Several pieces of evidence support the finding that deletions in
the SMA region are much more frequent in type I SMA patients
than in types II and III. Therefore, other different mutational
mechanisms could operate in types II and III SMA chromosomes.
We have described putative gene conversion events in affected
and normal chromosomes, and a duplication of the telomeric
copy. Therefore, the loss of SMN and the gain of one cBCD541
copy in one chromosome might be caused by a gene conversion
event. This mechanism could explain the increased dose of
cBCD541 mainly detected in parents of types II and III SMA
patients. Besides, we have detected parents carrying four or more
cBCD541 copies per diploid genome, suggesting that other
rearrangements such as duplications might occur in the SMA
region.
In conclusion, our genetic data provide evidence for an inverse
relationship between the number of cBCD541 copies and severity
of the SMA phenotype as previously suggested by Lefebvre et al.
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(17). Further studies are necessary to understand the putative role
of cBCD541 and other genes in the disease.
MATERIALS AND METHODS
SMA families
We analyzed 65 SMA families, 28 of type I, 28 of type II and nine
of type III. Patients fulfilled the diagnostic criteria defined by the
International SMA Consortium (29). DNA was extracted from
peripheral blood by the salting out method (30).
NAIP analysis
Deletion of the NAIP gene was analyzed by using exon 5 primers
(1863 and 1864) and exon 13 primers (1258 and 1343) in a
multiplex PCR reaction performed as previously described (20).
As amplification of exon 13 was less effective, another primer
pair (116CA1R and 116CA1F) was included to amplify the
microsatellite D5S1416 as an additional internal control (10).
Three fragments of 435 (exon 5), 213 (exon 13) and 140 bp
(D5S1416) were resolved on 1.4% agarose gels.
SSCP analysis of SMN exons 7 and 8
In order to amplify exon 7 we selected primers R111 (17) and
SMN7-B (5′ TTA ATT TAA GGA ATG TGA GCA C 3′). Exon
8 was amplified by using primers SMN8-A (5′ TAT GTA ATA
ACC AAA TGC AAT G 3′) and SMN8-C (5′ ATA AAC TAC
AAC ACC CTT CTC A 3′).
The primers SMN8-A or SMN7-B were 5′ end labeled with
γΖ32P]-dATP (5000 Ci/mmol; Amersham) by using T4 poly-
nucleotide kinase (31).
PCR reactions were performed in 20 µl and contained 200 ng
of genomic DNA, 1.5 pmoles of labeled primer, 18 pmoles of cold
primer (SMN8-C or R111), 200 µM of each dNTP, standard
Perkin Elmer PCR 1 × buffer, 1.5 mM MgCl2 and 1 U Taq DNA
polymerase. Samples were processed through 25 cycles consist-
ing each one of 45 s at 94C, 1 min at 55C (exon 8) or 57C
(exon 7) and 1 min at 72C.
Samples were mixed with 20 µl of formamide loading buffer
(95% formamide, 10 mM NaOH, 0.05% xylene cyanol and
0.05% bromophenol blue) and denatured for 10 min at 94C; then
2–5 µl were loaded on a 0.5 × MDE gel and electrophoresed in
the running conditions described elsewhere (17). Gels were dried
and autoradiographed. The use of a 5′ end-labeled primer makes
the resulting band pattern simpler because only two single strand
bands are revealed.
Densitometric analysis of the telomeric and centromeric SSCP
bands was carried out on a Desktop plus 3008 densitometer with
the Diversity One v1.0 software. The cBCD541/SMN dose ratios
were calculated, and final values were the average of at least two
independent PCR and SSCP experiments.
DdeI digestion analysis of SMN exon 8
PCR amplification of SMN exon 8 was performed by using either
the primers SMN8-A and SMN8-C, detailed above, or the
external primers SMN8-D (5′ TGG GTA ACT CTT CTT GAT
TAA A 3′) and SMN8-E (5′ AAG TAT GCA AAT TAA GAC
AGT C 3′).
PCR reactions were carried out in a final volume of 25 µl
containing 75 ng of genomic DNA, 20 pmoles of each primer,
200 µM each dNTP, standard Perkin Elmer PCR 1 × buffer,
1.5 mM MgCl2 and 1 U Taq DNA polymerase (Perkin Elmer).
Samples were subjected to 30 cycles of amplification consisting
each one of 1 min at 94C, 1 min at 55C and 1 min at 72C.
For differentiating the centromeric exon 8 from the telomeric
one, PCR products were digested with DdeI (Boehringer
Mannheim) because only the centromeric copy is cleaved by this
enzyme (32).
Genomic PCR amplification from exon 7 to exon 8
Amplification of the SMN gene from exon 7 to exon 8 was carried
out by using the Expand High Fidelity enzyme system (Boeh-
ringer Mannheim) and the primers SMN78-F (5′ TTT AAC TTC
CTT TAT TTT CCT TAC AGG G 3′) and SMN78-R (5′ CAC
ATA CGC CTC ACA TAC ATT TTG TT 3′) located at the 3′ end
of intron 6 and at the exon 8, respectively. These primers
amplified a fragment of about 1 kb.
The final volume was 50 µl and the reaction contained: 300 ng
of genomic DNA, 40 pmoles of each primer, 200 µM of each
dNTP, 1 × buffer supplied by the manufacturer and 2 U of the
enzyme mix. Thirty-five PCR cycles were run, consisting each
one of: 30 s at 94C, 30 s at 67C and 2 min at 72C increasing
this last step by 6 s per cycle. A final extension of 15 min at 72C
was performed.
Cloning and sequence
PCR products were cloned into the T-vector pMosBlue (Amer-
sham). Recombinant clones were reamplified and analyzed by
SSCP as above indicated. Selected clones carrying centromeric,
telomeric or polymorphic fragments were sequenced by using the
dideoxy chain termination method and Sequenase v2.0 (USB).
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